Get the Stockscreener App
261.91
0.45%
1.17
Natera Inc stock is traded at $261.91, with a volume of 3.40M.
It is up +0.45% in the last 24 hours and up +30.36% over the past month.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
See More
Previous Close:
$260.74
Open:
$262.42
24h Volume:
3.40M
Relative Volume:
2.28
Market Cap:
$37.51B
Revenue:
$2.50B
Net Income/Loss:
$-226.32M
P/E Ratio:
-159.58
EPS:
-1.6412
Net Cash Flow:
$71.51M
1W Performance:
+13.18%
1M Performance:
+30.36%
6M Performance:
+12.05%
1Y Performance:
+55.74%
1-Day Range:
$257.07
$270.43
1-Week Range:
$219.50
$271.47
52-Week Range:
$131.81
$271.47
Natera Inc Stock (NTRA) Company Profile
Name
Natera Inc
Sector
Industry
Phone
650-249-9090
Address
13011 MCCALLEN PASS, AUSTIN, CA
Compare NTRA vs TMO, DHR, IDXX, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NTRA
Natera Inc
|
261.91 | 37.34B | 2.50B | -226.32M | 71.51M | -1.6412 |
TMO
Thermo Fisher Scientific Inc
|
513.03 | 187.95B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
196.19 | 136.75B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
551.50 | 43.78B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
136.01 | 38.27B | 7.23B | 1.41B | 1.09B | 4.979 |
Natera Inc Stock (NTRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-14-26 | Initiated | William Blair | Outperform |
| Jan-07-26 | Initiated | Citigroup | Buy |
| Dec-02-25 | Resumed | Morgan Stanley | Overweight |
| Oct-27-25 | Upgrade | BNP Paribas Exane | Underperform → Neutral |
| Sep-22-25 | Resumed | Wells Fargo | Equal Weight |
| Mar-13-25 | Initiated | RBC Capital Mkts | Outperform |
| Jan-23-25 | Initiated | Barclays | Overweight |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-08-24 | Resumed | Craig Hallum | Buy |
| Feb-20-24 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-29-23 | Reiterated | BTIG Research | Buy |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Nov-13-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-28-23 | Initiated | Bernstein | Mkt Perform |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-05-23 | Initiated | UBS | Buy |
| Jan-18-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Apr-25-22 | Initiated | Stephens | Overweight |
| Mar-08-22 | Initiated | Goldman | Buy |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| May-25-21 | Initiated | Wells Fargo | Overweight |
| Jan-28-21 | Initiated | Truist | Buy |
| Oct-08-20 | Initiated | BTIG Research | Buy |
| Sep-28-20 | Initiated | Morgan Stanley | Overweight |
| Sep-17-20 | Initiated | SVB Leerink | Outperform |
| Jun-10-20 | Resumed | Piper Sandler | Overweight |
| May-07-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-05-18 | Initiated | JP Morgan | Neutral |
| Jul-05-18 | Reiterated | Piper Jaffray | Overweight |
| Aug-07-17 | Reiterated | Morgan Stanley | Overweight |
| Nov-10-16 | Reiterated | The Benchmark Company | Buy |
| May-23-16 | Reiterated | The Benchmark Company | Buy |
| May-11-16 | Reiterated | The Benchmark Company | Buy |
| Apr-19-16 | Initiated | The Benchmark Company | Buy |
| Sep-28-15 | Upgrade | Wedbush | Neutral → Outperform |
| Aug-14-15 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-04-15 | Initiated | Robert W. Baird | Outperform |
| Jul-27-15 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-27-15 | Initiated | Piper Jaffray | Overweight |
| Jul-27-15 | Initiated | Wedbush | Neutral |
View All
Natera Inc Stock (NTRA) Latest News
Natera director Herm Rosenman sells $4.13m in common stock - Investing.com UK
Form 4 Natera Inc For: 26 June By Investing.com - Investing.com Nigeria
Natera(NTRA.US) Officer Sells US$8.46 Million in Common Stock - Moomoo
Insider Sell Alert: Herm Rosenman Sells 16,530 Shares of Natera Inc (NTRA) - GuruFocus
Natera legal officer Daniel Rabinowitz sells $8.45m in shares - Investing.com
Natera (NTRA) director’s 10b5-1 sale leaves 4,250 shares - Stock Titan
Natera (NTRA) chief legal officer sells 33,600 shares in pre-set 10b5-1 trades - Stock Titan
Natera legal officer Daniel Rabinowitz sells $8.45m in shares By Investing.com - Investing.com India
Natera director Herm Rosenman sells $4.13m in common stock By Investing.com - Investing.com India
Natera (NTRA) Partners With Eledon To Put Prospera Into Phase 3 Kidney Trial - simplywall.st
Natera: All-Time Share Price High A Potential Caveat For Investors, Despite Promise - Seeking Alpha
Bernstein resumes Natera stock coverage with outperform rating - Investing.com UK
What's Driving Natera's Recent Stock Action, and Why Are Insiders Selling - Kavout | AI
NTRA Reiterated by Bernstein -- Price Target Announced at $310 - GuruFocus
Bernstein Maintains Natera(NTRA.US) With Buy Rating, Raises Target Price to $310 - Moomoo
What's Driving Natera's Recent Stock Action - Kavout | AI
Bernstein resumes Natera stock coverage with outperform rating By Investing.com - Investing.com Canada
Natera (NTRA) Receives Outperform Rating and $310 Target from Be - GuruFocus
Natera, Inc. Actuals & Estimates (NASDAQ:NTRA) - TradingView
Banu Saritas-Yildirim: Signatera is Approved in Japan by FDA - Oncodaily
Eledon Teams Up With Natera on Phase 3 Study - Orange County Business Journal
NTRA Forecast — Price Target — Prediction for 2027 - TradingView
NTRA's Signatera Secures PMDA Approval for MRD Testing in CRC in Japan - The Globe and Mail
Natera’s Prospera test selected for Eledon kidney transplant trial - Investing.com UK
Natera, Eledon Partner to Use Prospera in Phase 3 Kidney Transplant Trial - Moomoo
Natera’s Prospera test selected for Eledon kidney transplant trial By Investing.com - Investing.com South Africa
Natera (NTRA) Stock Jumps 10.7%: Will It Continue to Soar? - Yahoo Finance Singapore
Natera And Eledon Announce Strategic Partnership For Prospera™ Monitoring In Planned Phase 3 Kidney Transplant Trial - TradingView
Eledon trial will use Natera’s Prospera test to track kidney rejection - Stock Titan
Biotech Medical Test Leader Hits Record High, Joins 15 Others New To Best Stock Lists - Investor's Business Daily
Form 144 NATERA For: 24 June By Investing.com - Investing.com Nigeria
[144] Natera, Inc. SEC Filing - Stock Titan
This Medtech Stock Just Flashed A Buy Signal; Here's Why - Investor's Business Daily
Natera NTRA Jumps As NCCN Endorsement Fuels Bullish Targets - StocksToTrade
Natera Inc stock hits all-time high at 256.57 USD By Investing.com - Investing.com Australia
NTRA Maintained by BTIG -- Price Target Raised to $275 - GuruFocus
Natera Stock Jumps As NCCN Endorses Signatera MRD Test - timothysykes.com
Natera Secures Landmark Japan Nod For Signatera In Colorectal Cancer - Benzinga
Natera (NTRA) Achieves First MRD Test Approval in Japan - GuruFocus
Natera Surges As Signatera Wins Big Cancer Milestones - TipRanks
Natera (NTRA) Is Up 6.7% After First PMDA-Approved MRD Test in JapanWhat's Changed - simplywall.st
Natera Inc stock hits all-time high at 256.57 USD - Investing.com
Natera Stock Jumps as Investors Focus on Fresh Clinical Data and Strong Growth Outlook - Moomoo
Natera stock jumps as investors focus on fresh clinical data and strong growth outlook - Quiver Quantitative
Why Natera (NTRA) Stock Is Up Today - TradingView
Natera (NTRA) Stock Soars 7% Following Japanese Regulatory Milestone for Signatera - Blockonomi
Natera, Inc. (NTRA) Stock: Surges 7% as Signatera Wins Japan Approval - CoinCentral
A Quick Look at Today's Ratings for Natera(NTRA.US), With a Forecast Between $249 to $285 - Moomoo
ETFs Investing in Natera, Inc. Stocks - TradingView
Why Natera (NTRA) Is Up 6.7% After Japan Approves First MRD Test for Colorectal Cancer - Yahoo Finance
Signatera™ Receives Regulatory Approval in Japan for Colorectal Cancer - Yahoo Finance Singapore
Natera Inc Stock (NTRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.66%
0.37%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):